The future is upon us, page-12

side point... but thought would ask what others thought about one of the slightly longer term avenues for ResApp commercialization.



as discussed in the prospectus below.... last of point of five targets - namely..... BIG DATA INSIGHTS

might be a decent avenue for cash if this goes ahead?

pharma and gov sounds like real dollars.




government reference may even suggest assisting (a long way down the tract) in monitoring some of the more feared outbreaks from recent years eg SARS / swine flu / bird flu.

sounds like the movies.... but may be an area the RAP backers/UNIQUEST may have considered.




ResApp media focus to date..... seems to have been very much on "mum and dad" users of the app.... though prospectus seems to have quite a wider field of sales avenues in mind.


early days.... just a thought

--------------

http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=rap&timeframe=Y&year=2015


see replacement prospectus 26/05/2015

----------------------------------


Business model
4.4

ResApp plans to pursue multiple revenue streams in commercialisation of the technology:


(c) Telehealth partnerships and licensing

With the telehealth market growing at a rapid rate, partnerships with major telehealth providers would allow ResApp to quickly benefit from these providers’ large and growing customer base.
ResApp’s technology would provide telehealth providers a unique capability that would significantly enhance the breadth of consultations available to their customers and their network of doctors.

ResApp could license the ResApp algorithms to telehealth providers for integration into their existing telehealth systems, could provide an application programming interface (API) into a cloud-hosted service or could provide a standalone application that communicates to the telehealth providers servers.

ResApp would aim to charge a fee per diagnostic test or a monthly subscription fee for chronic disease management.


(d) Direct app sales to consumers

After obtaining the required regulatory approvals, ResApp plans to make direct app sales to consumers via app stores such as the Apple AppStore and Google Play. These stores provide a unique opportunity to reach the huge smartphone user market without large distribution or shipping costs.

ResApp expects to charge a small nominal fee for purchasing and downloading the app, however its expects the majority of revenue to come from in-app purchases associated with per diagnostic test, or monthly subscriptions in the case of management of chronic conditions.


(e) Mobile and wearable device manufacturers and telecoms service providers partnerships and licensing

By partnering with mobile or wearable device manufacturers, or with telecoms providers, there is the potential for preloading ResApp applications on devices (i.e. the application would be already installed on the device before it reaches the end user).

Both of these groups already preload multiple applications via partnerships with applications developers. This would allow ResApp to access a significant installed base, and would potentially provide revenue through preload fees, in-app purchases or monthly subscriptions.


(f) Partnerships with aid and humanitarian agencies

To reach the large numbers of potential users in the resource-poor developing world, ResApp plans to partner with global aid and humanitarian agencies who have existing well-developed logistics networks in these regions. These agencies have a critical need for low cost and accurate diagnostic tools that are usable not only by trained medical professionals, but also untrained personnel operating under difficult field conditions.

In the license agreement of the Licensed IP from UniQuest to ResApp, ResApp agreed to comply with the Global Access Objectives of the Bill and Melinda Gates Foundation. This requires that the product be made accessible (with respect to cost, quantity and applicability) to the people most in need within the developing countries of the world.


(g) Big data insights

Once in wide use, anonymized data collected by ResApp (with the permission of users) could provide unprecedented insight into respiratory conditions for researchers at large pharmaceutical companies, medical device companies, universities, medical research institutes and government agencies.

Data could be collated and further analysed by ResApp to provide information on the occurrence, spread and effectiveness of treatment options. This data could be licensed or could be provided through a software-as-a-service.

---------------------------


bsh